Clinical TrialsSearch results
Number of results: 1090
Recruiting
- OGSG2101:Efficacy and Safety of BEACON triplet regimen for early relapse BRAF-mutated colorectal cancer
- BRAF V600E-mutated colorectal cancer
- KAGAWA Yoshinori
- 2022-01-13
Other
- Outcome Assessment using SF-36 v2 in Stroke Patient Study
- Brain infarction
- OASIS STUDY Research Group
- 2008-05-31
Not yet recruiting
- Clinical research on a neuroprotective effect of minocycline treatment in the acute stage of Ischemic Stroke
- Brain Infarction
- Takeshi Takahashi
- 2009-08-14
Other
- analysis of immunocytes in patients with brain tumor treated with temozolomide
- brain tumor
- Department of Neurosurgery, Osaka University Graduate School of Medicine
- 2008-07-01
Other
- Validation study of algorithms predicting axillary lymph node metastasis from primary breast cancer and predicting the treatment response to neoadjuvant chemotherapy.
- Breast cancer
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University
- 2009-06-24
Other
- Sequential chemotherapy with FEC(fluoraouracil, epirubicin and cyclophosphamide) and P+H(weekly Paclitaxel+Trastuzumab) as primary systemic therapy for operable breast cancer with HER2 positive disease-a phase 2 study
- Breast Cancer
- Breast Cancer PST Study Group
- 2005-10-16
Other
- Second-line Trastuzumab/Docetaxel combination therapy in patients with HER2-positive metastatic breast cancer(MBC)- a phase 2 study
- Breast cancer
- H/D study group on Breast Cancer
- 2005-10-15
Other
- Randomized Phase II Study of Neoadjuvant Chemotherapy and Trastuzumab (Herceptin) for Operable Breast Cancer with Overexpression of HER2
- Breast Cancer
- Office for cordination of Herceptin trial
- 2007-03-23
Other
- Randomized controlled trial on effectiveness of ultrasonography in breast cancer screening(Japan Strategic Anti-Cancer Randomized Trial)
- Breast Cancer
- Division of Surgical Oncology, Graduate School of Medicine, TOHOKU UNIVERSITY
- 2007-07-01
Other
- Phase II study of neoadjuvant treatment with Exemestane for 24 weeks in postmenopausal women with hormone receptor positive Stage II or IIIA breast cancer.
- Breast Cancer
- Japanese Foundation for Multidisciplinary Treatment of Cancer
- 2006-03-06